Related Experiment Videos
Gene-based therapy for hypertension--do preclinical data suggest a promising future?
Giovanni Maria Puddu1, Eleonora Cravero, Eleonora Ferrari
1Department of Internal Medicine and Aging, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Cardiology
|September 14, 2006
Summary
Gene therapy offers promising long-term blood pressure control using vasodilator genes or antisense approaches. Future clinical applications may manage essential hypertension and its complications.
Area of Science:
- Molecular biology
- Cardiovascular medicine
- Pharmacogenomics
Background:
- Experimental studies demonstrate gene therapy's potential for sustained blood pressure regulation.
- Hypertension management remains a significant clinical challenge, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review gene-based approaches for controlling blood pressure.
- To discuss the mechanisms and delivery methods of gene therapy in hypertension.
Main Methods:
- Overview of 'sense' gene therapy (e.g., endothelial nitric oxide synthase) and 'antisense' therapy (e.g., targeting angiotensin-converting enzyme).
- Exploration of RNA-based inhibition strategies like ribozymes and small interfering RNAs.
- Discussion of gene delivery vectors, including viral and non-viral options (plasmids, liposomes).
Main Results:
- Both sense and antisense gene therapy approaches have shown efficacy in experimental models.
- Various RNA molecules can effectively inhibit gene function relevant to blood pressure regulation.
- Delivery methods, including viral and non-viral vectors, present distinct advantages and limitations.
Conclusions:
- Gene therapy holds potential for long-term management of essential hypertension.
- Despite current limitations, clinical translation for hypertension and its sequelae is a future possibility.
- Further research and development are needed to overcome delivery and safety challenges for clinical application.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...